By analyzing the expression of CTLA-4 at different ER, PR, Her-2 expression status in different breast cancer samples, we concluded that the expression of CTLA-4 was higher in the samples of breast cancer patients with negative estrogen receptor expression, while the expression of CTLA-4 was not statistically significant at different Her-2 expression levels. Here, ERBB2 is linked to breast cancer.